{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-25-000077","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.535414+00:00","generated_at":"2026-05-17T01:58:22.378491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M","bullets":["Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.","Operating expenses $15.5M, down 19% from $19.1M year-over-year.","Cash and investments $168.5M as of Sept 30, 2025.","Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-25-000077","json":"https://secwatch.observer/filing/0001808805-25-000077.json","markdown":"https://secwatch.observer/filing/0001808805-25-000077.md","text":"https://secwatch.observer/filing/0001808805-25-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/0001808805-25-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/naut-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:58:22.378491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}